Navigation Links
Aspirin still overprescribed for stroke prevention in AF
Date:1/28/2014

Sophia Antipolis, 28 January 2014: Aspirin is still overprescribed for stroke prevention in atrial fibrillation (AF) despite the potential for dangerous side effects, according to research published today.

Professor Gregory Y.H. Lip, lead author of the European Society of Cardiology (ESC) study, said: "The perception that aspirin is a safe and effective drug for preventing strokes in AF needs to be dispelled. If anything, you could say that giving aspirin to patients with AF is harmful because it is minimally or not effective at stroke prevention, yet the risk of major bleeding or intracranial haemorrhage is not significantly different to well-managed oral anticoagulation."

He added: "All the contemporary guidelines1 say that aspirin should not be used for the prevention of stroke in patients with AF. And yet our study shows that aspirin is still overprescribed in these patients."

Stroke prevention is central to the management of patients with AF. As the most common cardiac rhythm disorder, AF occurs in 1.5-2% of the general population in the developed world and people over the age of 40 have a 1 in 4 lifetime risk of developing AF.2 Patients with AF have a five-fold risk of stroke, and when they do have strokes they lead to more death and disability.3

Prevention of strokes in patients with AF is based on identification of risk factors.2 Patients with no stroke risk factors (ie. CHA2DS2-VASc score of 0 in males or 1 in females) are considered 'low risk' and do not need any antithrombotic drugs. Patients with one or more risk factors should be offered effective stroke prevention, and thus be given an oral anticoagulant (warfarin or one of the novel oral anticoagulants). The use of aspirin, either alone or in combination with an oral anticoagulant, is not recommended.

The study published online today in the American Journal of Medicine provides the most up-to-date picture of European cardiologists' prescribing of antithrombotic treatment, which includes oral anticoagulation therapy (warfarin and the novel oral anticoagulants) and antiplatelet drugs (mainly aspirin).4 The data are from the EORP Atrial Fibrillation General Pilot Registry of more than 3 100 patients in nine countries.5

Overall the study found that the use of oral anticoagulants has improved over the last decade since the last Euro Heart Survey was performed. Where oral anticoagulation was used, most patients (72%) were prescribed warfarin and just 8% were prescribed a new oral anticoagulant.

Professor Lip said: "Novel oral anticoagulant uptake is still a bit low, probably because of differences in regulatory approval, costs and access to drugs in different countries. But the main point is that overall oral anticoagulant uptake as a whole has improved in the last 10 years."

Aspirin was commonly prescribed, either alone or in combination with an oral anticoagulant, when patients had myocardial infarction or coronary artery disease. The strongest reason to prescribe both drugs was coronary artery disease, which increased the use of combined therapy by more than eight-fold.

Professor Lip said: "Aspirin is still overused for stroke prevention in AF. ESC guidelines say concomitant aspirin should not be given to anticoagulated AF patients with stable vascular disease. The combination of drugs does not reduce cardiovascular events and stroke but does increase the risk of bleeding."

Another worrying finding was that oral anticoagulants were underprescribed in elderly patients, with aspirin alone more commonly prescribed. Professor Lip said: "Elderly patients are at the highest risk for stroke and yet they are given aspirin which is not recommended and potentially harmful. There is a perception that elderly patients do not do well on anticoagulation. But a number of studies now, including BAFTA,6 have shown that in elderly patients warfarin is far superior to aspirin in preventing stroke."

Patients with paroxysmal AF were less likely to receive oral anticoagulation compared to patients with permanent AF. Professor Lip said: "Cardiologists are continuing to underprescribe anticoagulation in paroxysmal AF and the belief that these patients are at less risk is another myth. ESC guidelines say that AF patients with stroke risk factors should receive oral anticoagulation irrespective of the type of AF."

Professor Lip concluded: "Our study of antithrombotic prescribing by cardiologists reveals a positive trend of increasing oral anticoagulant use. But worrying misconceptions and practices remain regarding aspirin, treatment of the elderly and paroxysmal AF."


'/>"/>

Contact: ESC Press Office
press@escardio.org
33-049-294-7756
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Report says new evidence could tip the balance in aspirin cancer prevention care
2. Aspirin as Effective as Warfarin for Heart Failure: Study
3. Some Diabetics May Not Benefit From Daily Aspirin
4. Aspirin protects against Barretts esophagus
5. Study adds to evidence daily aspirin linked to lower cancer mortality
6. Daily aspirin usage associated with lower cancer mortality
7. Daily Aspirin May Cut Cancer Deaths, Another Study Finds
8. Daily Aspirin May Help Fight Prostate Cancer, But Not Breast Cancer
9. Aspirin may help men with prostate cancer live longer, study suggests
10. Adding Plavix to Aspirin Doesnt Help Guard Against Second Stroke: Study
11. Gene mutation identifies colorectal cancer patients who live longer with aspirin therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... Sabah Shah MD, MBA has joined the Retina ... of New York was founded by James M. Maisel, MD and has been providing tertiary ... has always followed a legacy of surpassing expectations amongst her peers. Growing up in ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Surgical Facial Rejuvenation" at the 2016 Anti-Aging & Beauty Awards at The ... The Aesthetic & Anti-aging Medicine European Congress (AMEC) brings together the industry’s ...
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in New York City, with long-time partners The Paul Foundation, on November 10, ...
(Date:12/4/2016)... ... 03, 2016 , ... Penrose Senior Care Auditors® was announced ... evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony and Banquet ... for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ingenuity, commitment ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges on regular brushing of ... optimal results. This important necessity inspired an inventor from Las Vegas, Nev., to design ... that people break or avoid bad techniques of brushing the teeth in order to ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Israel , December 5, 2016 ... identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase ... BL-8040, the Company,s leading oncology platform at the ongoing 58th ... San Diego, California . ... , , ...
(Date:12/5/2016)... Taiwan , Dec. 5, 2016 ... non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) ... profile of ropeginterferon alfa-2b versus HU AOP ... follow-up trial CONTINUATION-PV to obtain European marketing authorization in the ... data to the FDA as it seeks approval for commercialization ...
(Date:12/4/2016)... --  Pairnomix, LLC, a genetic research company and member ... White House, today announced that findings from its first case ... therapies for a patient with epileptic encephalopathy caused by a ... the 70 th Annual Meeting of the American ... December 2-6, 2016.  Pairnomix, unique process involves creating ...
Breaking Medicine Technology: